PET/CT Scan as a Surrogate for Treatment Outcomes in Pulmonary Sarcoidosis

Nidah Shabbir Khakoo  
University of Miami School of Medicine

Safayeth Jabeen Isma  
University of Miami School of Medicine

Mehdi Mirsaeidi ( msm249@med.miami.edu )  
University of Miami School of Medicine  https://orcid.org/0000-0001-5298-8442

Research article

Keywords: 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET), pulmonary sarcoidosis, standardized uptake value (SUV).

DOI: https://doi.org/10.21203/rs.3.rs-39748/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background:** One of the challenges in treating sarcoidosis is that there is currently no reliable modality to measure disease activity and prognosis. This study was conducted to determine if PET/CT scans could be used to evaluate clinical response to sarcoidosis treatment.

**Methods:** In a retrospective cohort study, subjects with symptomatic pulmonary sarcoidosis followed by the University of Miami Sarcoidosis program from 2015 through 2018 were assessed. Inclusion criteria were subjects $\geq 18$ years who had histologically-confirmed pulmonary sarcoidosis for $\geq 2$ years. Subjects that had PET/CT scans completed prior to starting treatment and approximately one year later were enrolled. Demographics, circulatory blood biomarkers, subjective symptoms, and medications were recorded at baseline (T0) and a year later (T1).

**Results:** Ten subjects with symptomatic pulmonary sarcoidosis were enrolled. All subjects had at least one organ affected by sarcoidosis and a highest of five organs involved (mean 2.75, SD 1.21). Mean serum angiotensin-converting enzyme (ACE) level was 56.0 U/L (SD 43.08), mean lysozyme was 7.78 µg/mL (SD 3.78), and mean C-reactive protein (CRP) was 0.73 mg/dL (SD 0.85) at T0. Further, mean number of positive lesions was 4.27 (SD 2.65) and mean highest SUV was 5.59 (SD 3.59), with a highest of 14.5 at T0. After one year of therapy, a significant improvement in measured outcomes was noted. Dyspnea was absent in all subjects at T1 and only 1 (10%) reported cough at T1. The mean ACE was 42.17 U/L (SD 20.24), mean lysozyme was 6.24 µg/mL (SD 0.80), and mean CRP was 1.67 mg/dL (SD 1.60) at T1. Furthermore, five (50%) subjects were receiving a reduced dose of their respective medication at T1. In terms of PET/CT findings, the mean number of positive lesions decreased at T1 to 1.73 (SD 2.87) and the mean highest SUV decreased to 2.18 (SD 3.3).

**Conclusion:** PET/CT scans can be used as a surrogate modality to help guide treatments in those subjects affected by sarcoidosis, as shown by significant reductions in the involvement of multiple organs. Further studies with larger sample sizes are necessary to explore the potential PET/CT scans have to influence treatment outcomes in sarcoidosis.

Background

Sarcoidosis is a multi-organ disease of unknown etiology, characterized by the formation of non-necrotizing epithelioid granulomas which can affect any organ, but has a predilection for lung involvement (1, 2). Epidemiologically, sarcoidosis affects approximately 10 out of every 100,000 subjects per year in the United States, is present in all ethnic groups, and has a peak onset in adults between 20 and 40 years of age (3–5). Sarcoidosis has an unpredictable clinical presentation, ranging from incidentally discovered radiographic abnormalities in an asymptomatic patient to chronic progressive illness affecting multiple organ systems (6).

The initial evaluation of patients with suspected sarcoidosis involves a battery of tests, including blood cell counts, serum chemistry, urinalysis, and biomarkers (7, 8). In those with pulmonary symptoms,
pulmonary function tests (PFTs) and chest images are usually obtained. However, one of the difficulties in treating this condition is that there is currently no single test to monitor the response to therapy or monitor disease activity.

Positron emission tomography (PET)/computed tomography (CT) scans are widely used in the assessment of subjects with suspected or confirmed malignancies. There are limited small series and case reports addressing the use of PET/CT scans with a glucose analogue of 18F-fluorodeoxyglucose (18-FDG) for the assessment of inflammatory diseases (9–11). The advantage of PET/CT scans is that it visualizes FDG accumulation in activated inflammatory cells and provides whole-body images, allowing clinicians to assess the activity of sarcoidosis throughout the body. However, little is known regarding the role of PET/CT scans in the evaluation of the response to sarcoidosis treatment. The aim of this study was to understand whether PET/CT scans can be used to monitor disease outcomes and treatment responses.

**Methods**

This is a retrospective case series which included ten subjects with symptomatic pulmonary sarcoidosis that were followed by the University of Miami (UM) Sarcoidosis Program from 2015 to 2018. Subjects were ≥ 18 years and had histologically-confirmed pulmonary sarcoidosis for ≥ 2 years. Our sarcoidosis program has an active patient registry that has been approved by the Institutional Review Board (IRB) of the university and all participants have provided written consent. Subjects that had PET/CT scans completed prior to starting treatment and approximately one year later were enrolled. Patients who were unwilling to consent to the IRB-approved protocol were excluded. In addition, patients without evidence of pulmonary sarcoidosis, patients with a history of cancer, or patients who had PET/CT scans done > 1 year apart were excluded.

Demographics, symptoms, biomarkers, medications and imaging were recorded at baseline (T₀) and approximately one year after starting therapy (T₁). Positive pulmonary lesions were defined as either involving the parenchyma, mediastinal lymph nodes, or both. The study outcomes were symptom resolution, radiological (PET/CT) improvement, and reduction in the total dose of medication.

**Results**

The baseline characteristics of the study population were as follows: 3 (30%) subjects were female, 4 (40%) were African-Americans, 5 (50%) were European-American, and 1 (10%) was Latino. Mean age (standard deviation, SD) was 58.36 years (10.05). All subjects had at least one organ involved and a highest of five organs involved (mean 2.75, SD 1.21). Six subjects (60%) had dyspnea, 3 (30%) had fatigue, and 5 (50%) had cough at T₀. The upper limit of normal for angiotensin-converting enzyme (ACE), lysozyme, and C-reactive protein (CRP) were 82 U/L, 12.8 µg/mL, and 0.5 mg/dL, respectively. Mean serum ACE level was 56.0 U/L (SD 43.08), mean lysozyme was 7.78 µg/mL (SD 3.78), and mean CRP was 0.73 mg/dL (SD 0.85). At T₀, 9 (90%) subjects were receiving steroids, 1 (10%) was receiving
methotrexate (MTX), and 1 (10%) was receiving azathioprine (AZA). All 10 (100%) subjects had positive pulmonary lesions on PET/CT scans. Mean number of positive lesions was 4.27 (SD 2.65). Mean highest SUV was 5.59 (SD 3.59), with a highest of 14.5 and lowest 2.7 at T₀.

After one year of therapy, a significant improvement in measured outcomes was noted. Dyspnea was absent in all subjects at T₁ compared to 6 (60%) at T₀, 1 (10%) had cough at T₁ compared to 5 (50%) at T₀, and the same number of subjects reported fatigue at T₁ as they did at T₀. Furthermore, 5 (50%) subjects were receiving a reduced dose of their respective medication at T₁. The mean ACE was 42.17 U/L (SD 20.24), mean lysozyme was 6.24 µg/mL (SD 0.80), and mean CRP was 1.67 mg/dL (SD 1.60) at T₁. Regarding the PET/CT findings, the mean number of positive lesions decreased to 1.73 (SD 2.87) and the mean highest SUV decreased to 2.18 (SD 3.3). Figure 1 shows a representative PET/CT scan imaging at baseline T₀ and after one-year T₁. Given the small sample size of this case series, we cannot correlate biomarker activity or changes in pulmonary function with PET/CT scans.

Conclusions

The current study suggests PET/CT scans can be used as a surrogate modality to help guide treatments in those subjects affected by sarcoidosis, as shown by significant reductions in the involvement of multiple organs. Larger longitudinal studies are necessary to explore the potential of PET/CT scans to influence sarcoidosis treatment protocols.

Abbreviations

**PFTs**: Pulmonary function tests

**PET**: Positron emission tomography

**CT**: Computed tomography

**UM**: University of Miami

**IRB**: Institutional Review Board

**ACE**: Angiotensin-converting enzyme

**CRP**: C-reactive protein

**MTX**: Methotrexate

**AZA**: Azathioprine

Declarations
**Ethics Approval and Consent to Participate**

The sarcoidosis program at the University of Miami has an active patient registry that has been approved by the Institutional Review Board (IRB) of the University of Miami (IRB: 20150612) and all participants have provided written consent.

**Consent for Publication**

Consent for publication has been obtained.

**Availability of Data and Materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing Interests**

The authors declare that they have no competing interests.

**Funding**

This manuscript did not entail any funding sources outside of our institution.

**Authors’ Contributions**

NSK and IJS conducted literature review, reviewed the charts, collected data, and helped in manuscript preparation. MM conducted literature review, visited the patients, and helped manuscript preparation.

**Acknowledgements**

Authors would like to thank Drs. Michael Campos and Mukunthan Murthi for their technical assistances.

**Authors’ Information**

1. Internal Medicine Residency Training Program, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL
   - NSK

2. Division of Pulmonary and Critical Care, Department of Medicine, University of Miami, Miami, FL, USA
   - IJS
   - MM

**References**
1. Ma YL, Gal A, Koss MN. The pathology of pulmonary sarcoidosis: update. Semin Diagn Pathol. 2007;24(3):150–61.
2. Al-Kofahi K, Korsten P, Ascoli C, Virupannavar S, Mirsaedi M, Chang I, et al. Management of extrapulmonary sarcoidosis: Challenges and solutions. Ther Clin Risk Manag. 2016;12:1623–34.
3. Mirsaedi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. Chest [Internet]. 2015;147(2):438–49. Available from: http://dx.doi.org/10.1378/chest.14-1120
4. Cozier YC. Assessing the worldwide epidemiology of sarcoidosis: Challenges and future directions. Eur Respir J [Internet]. 2016;48(6):1545–8. Available from: http://dx.doi.org/10.1183/13993003.01819-2016
5. Baughman RP, Field S, Costabel U, Crystal RG, Culver DA, Drent M, et al. Sarcoidosis in America: Analysis based on health care use. Ann Am Thorac Soc. 2016;13(8):1244–52.
6. Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU. Pulmonary sarcoidosis. Lancet Respir Med [Internet]. 2018;6(5):389–402. Available from: http://dx.doi.org/10.1016/S2213-2600(18)30064-X
7. Bickett AN, Lower EE, Baughman RP. Sarcoidosis Diagnostic Score: A Systematic Evaluation to Enhance the Diagnosis of Sarcoidosis. Chest [Internet]. 2018;154(5):1052–60. Available from: https://doi.org/10.1016/j.chest.2018.05.003
8. Baughman RP, Iannuzzi MC. Diagnosis of sarcoidosis: When is a peek good enough? Chest [Internet]. 2000;117(4):931–2. Available from: http://dx.doi.org/10.1378/chest.117.4.931
9. Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, Vucinic-Mihailovic V, Artiko V, Saranovic D, et al. The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med. 2012;53(10):1543–9.
10. Öksüz MÖ, Werner MK, Aschoff P, Pfannenberg C. 18F-FDG PET/CT for the diagnosis of sarcoidosis in a patient with bilateral inflammatory involvement of the parotid and lacrimal glands (panda sign) and bilateral hilar and mediastinal lymphadenopathy (lambda sign). Eur J Nucl Med Mol Imaging. 2011;38(3):603.
11. Pellegrino D, Bonab AA, Dragotakes SC, Pitman JT, Mariani G, Carter EA. Inflammation and infection: Imaging properties of 18F-FDG- labeled white blood cells versus 18F-FDG. J Nucl Med. 2005;46(9):1522–30.

Table 1

Table 1: Demographic and radiographical findings of the included subjects with pulmonary sarcoidosis
| Case | Age | Gender | Ethnicity     | Highest SUV, $T_0$ | Number of Positive Lesions, $T_0$ | Highest SUV, $T_1$ | Number of Positive Lesions, $T_1$ |
|------|-----|--------|--------------|--------------------|----------------------------------|--------------------|----------------------------------|
| 1    | 42  | Male   | European-American | 4.6                | 4                                | 2.6                | 3                                |
| 2    | 47  | Male   | African-American  | 4.3                | 2                                | 2.6                | 1                                |
| 3    | 48  | Male   | European-American | 9.1                | 3                                | 0                  | 1                                |
| 4    | 52  | Male   | European-American | 14.5               | 6                                | 0                  | 0                                |
| 5    | 56  | Female | African-American  | 2.7                | 2                                | 1.5                | 2                                |
| 6    | 63  | Male   | European-American | 2.9                | 2                                | 0                  | 0                                |
| 7    | 67  | Male   | African-American  | 7.5                | 8                                | 11.3               | 10                               |
| 8    | 70  | Female | African-American  | 3                  | 4                                | 0                  | 0                                |
| 9    | 68  | Male   | European-American | 3.5                | 10                               | 3.1                | 2                                |
| 10   | 70  | Female | Latino          | 5.43               | 5                                | 0                  | 0                                |

Figures
Figure 1

PET/CT scan imaging at baseline T0 (left) and after one year T1 (right). PET/CT imaging shows significant improvement after one year from the initial scan.